Switch theme
Sign up to access all valuation multiples
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
2018
322
LTM Revenue $363M
LTM EBITDA -$54.7M
$2.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mirum Pharmaceuticals has a last 12-month revenue of $363M and a last 12-month EBITDA of -$54.7M.
In the most recent fiscal year, Mirum Pharmaceuticals achieved revenue of $337M and an EBITDA of -$49.0M.
Mirum Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mirum Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $186M | $337M | XXX | XXX | XXX |
| Gross Profit | $64.7M | $139M | XXX | XXX | XXX |
| Gross Margin | 35% | 41% | XXX | XXX | XXX |
| EBITDA | -$136M | -$49.0M | XXX | XXX | XXX |
| EBITDA Margin | -73% | -15% | XXX | XXX | XXX |
| Net Profit | -$136M | -$163M | XXX | XXX | XXX |
| Net Margin | -73% | -49% | XXX | XXX | XXX |
| Net Debt | n/a | $20.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Mirum Pharmaceuticals's stock price is $40.
Mirum Pharmaceuticals has current market cap of $1.9B, and EV of $2.0B.
See Mirum Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0B | $1.9B | XXX | XXX | XXX | XXX | $-1.59 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Mirum Pharmaceuticals has market cap of $1.9B and EV of $2.0B.
Mirum Pharmaceuticals's trades at 5.4x LTM EV/Revenue multiple, and -36.2x LTM EBITDA.
Analysts estimate Mirum Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Mirum Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.0B | XXX | XXX | XXX |
| EV/Revenue | 5.9x | XXX | XXX | XXX |
| EV/EBITDA | -40.4x | XXX | XXX | XXX |
| P/E | -22.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -185.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMirum Pharmaceuticals's NTM/LTM revenue growth is 25%
Mirum Pharmaceuticals's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Mirum Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Mirum Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Mirum Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 81% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -15% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -64% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 10% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.0M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 42% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 102% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mirum Pharmaceuticals acquired XXX companies to date.
Last acquisition by Mirum Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Mirum Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Mirum Pharmaceuticals founded? | Mirum Pharmaceuticals was founded in 2018. |
| Where is Mirum Pharmaceuticals headquartered? | Mirum Pharmaceuticals is headquartered in United States of America. |
| How many employees does Mirum Pharmaceuticals have? | As of today, Mirum Pharmaceuticals has 322 employees. |
| Who is the CEO of Mirum Pharmaceuticals? | Mirum Pharmaceuticals's CEO is Mr. Christopher Peetz. |
| Is Mirum Pharmaceuticals publicy listed? | Yes, Mirum Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Mirum Pharmaceuticals? | Mirum Pharmaceuticals trades under MIRM ticker. |
| When did Mirum Pharmaceuticals go public? | Mirum Pharmaceuticals went public in 2019. |
| Who are competitors of Mirum Pharmaceuticals? | Similar companies to Mirum Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Mirum Pharmaceuticals? | Mirum Pharmaceuticals's current market cap is $1.9B |
| What is the current revenue of Mirum Pharmaceuticals? | Mirum Pharmaceuticals's last 12-month revenue is $363M. |
| What is the current EBITDA of Mirum Pharmaceuticals? | Mirum Pharmaceuticals's last 12-month EBITDA is -$54.7M. |
| What is the current EV/Revenue multiple of Mirum Pharmaceuticals? | Current revenue multiple of Mirum Pharmaceuticals is 5.4x. |
| What is the current EV/EBITDA multiple of Mirum Pharmaceuticals? | Current EBITDA multiple of Mirum Pharmaceuticals is -36.2x. |
| What is the current revenue growth of Mirum Pharmaceuticals? | Mirum Pharmaceuticals revenue growth between 2023 and 2024 was 81%. |
| Is Mirum Pharmaceuticals profitable? | Yes, Mirum Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
